Castration Resistant Prostatic Cancer: Clinical Trials

4 trials for Castration Resistant Prostatic Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 1, Recruiting 1, Terminated 1, Withdrawn 1
Phase 11Withdrawn 1

Follow Castration Resistant Prostatic Cancer: new trials by email Literature Review of Castration Resistant Prostatic Cancer trials Research Report on Castration Resistant Prostatic Cancer

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer
Phase 1 / Phase 2WithdrawnNuvation Bio Inc.2022-09-012022-08-05
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Docetaxel intermittent - Castration Resistant Prostatic Cancer
Phase 2TerminatedAustralian and New Zealand Urogenital and Prostate Cancer Trials Group62022-07-292024-11-22
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Omeprazole 80 mg twice daily - Prostate Cancer, Refractory Cancer
Phase 2RecruitingWake Forest University Health Sciences502021-03-052026-04-13
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Pembrolizumab, Chemotherapy - Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Phase 2CompletedUniversity of California, San Francisco262018-02-202024-11-20

Narrower conditions

Prostatic Neoplasms, Castration-Resistant (4)  ·  Prostatic Neoplasms (3)  ·  Neoplasms (1)

Broader conditions

Genital Diseases (4)  ·  Genital Diseases, Male (4)  ·  Genital Neoplasms, Male (4)  ·  Male Urogenital Diseases (4)  ·  Neoplasms by Site (4)  ·  Prostatic Diseases (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)  ·  Neoplasms (3)  ·  Prostatic Neoplasms (1)

Interventions

Drug Therapy (1)  ·  Omeprazole (1)  ·  enzalutamide (1)  ·  pembrolizumab (1)

Sponsors

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1)  ·  Nuvation Bio Inc. (1)  ·  University of California, San Francisco (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (3)  ·  Australia (1)

Top investigators

David Oh, MD (1)  ·  Kate Mahon (1)  ·  Michael Goodman, MD (1)

NIH funding

P30CA012197 (1), R01CA223484 (1)